<?xml version="1.0" encoding="UTF-8"?>
<p>Immune-associated disorders, including autoimmune diseases, viral or bacterial infections, and chronic diseases, are usually associated with acute inflammation, which represents a key component for the activation of immune response [
 <xref rid="B13-vaccines-08-00468" ref-type="bibr">13</xref>]. On the other hand, the chronicity of inflammatory response can negatively influence the immune function, affecting both innate immune cells and T and B lymphocytes, thus suggesting a possible usefulness of anti-inflammatory immunomodulators [
 <xref rid="B13-vaccines-08-00468" ref-type="bibr">13</xref>]. Accordingly, immunomodulatory agents, with antioxidant and anti-inflammatory activity, have attracted great attention as possible chemopreventive agents, due to their ability to counteract chronic inflammation, which provides favorable conditions for the transition from normal to cancer cell [
 <xref rid="B14-vaccines-08-00468" ref-type="bibr">14</xref>].
</p>
